Use of opioids as one of the causes of fever in patients with advanced cancer by Graczyk, Michał et al.
Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons 
Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial 
use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and 
Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
https://doi.org/10.1177/0394632016686088
International Journal of 
Immunopathology and Pharmacology
2017, Vol. 30(1) 98 –104
© The Author(s) 2017





Opioid treatment involves the risk of undesirable 
symptoms. One of the extremely rare and still 
poorly known symptoms is fever caused by the use 
of this medicine.
Keeping an appropriate body temperature is one 
of the basic homeostatic functions that are critical 
to survival of the organism. A particular integrating 
role is played by the hypothalamus where all infor-
mation concerning heat is integrated and, as a 
result, an autonomous, endocrine, motoric, and 
behavioral response is generated in order to adapt 
to the changes in the environment.1 There are mul-
tiple hypotheses concerning thermoregulation. 
According to Romanowsky, maintaining a constant 
central body temperature is the result of interaction 
of independent thermoeffector loops that have their 
own impulsation pathways, both afferent and effer-
ent.2 Depending on whether a given factor increases 
or reduces the body temperature (leading to hyper-
thermia or hypothermia), it affects to the same 
extent the thermal value of the areas in the hypo-
thalamus connected with the independent thermo-
effector networks called term balance point 
(previously set point) which works as a “thermo-
stat” and determines the central body temperature 
outside of the physiological values (the oscillation 
is in the range of 36.1–37.4°C).
The physiologically very complex process of 
maintaining a dynamic balance between heat pro-
duction, preservation, and loss can be disrupted in 
many situations. It can be influenced by intake of 
medicine, presence of hormonal disorders or vari-
ous medical conditions (e.g. cancer), as well as 
presence in disadvantageous environmental condi-
tions (Table 1).3 Diagnosis of fever and selection of 
the target procedure can be more difficult in the 
case of patients with simultaneous occurrence of 
many potential causes of thermoregulation disor-
ders, including episodic ones. Below is a descrip-
tion of a patient with advanced pancreatic cancer, 
with numerous complications of the cancer and 
with thermoregulation disorders observed both 
during the attempt to include a strong opioid in the 
pain therapy and during the regular treatment with 
a weak opioid in the maximum dose.
A 67-year-old patient with progressing weaken-
ing, lack of appetite, weight loss, jaundice, and itch 
was diagnosed with pancreatic adenocarcinoma 
infiltrating the duodenum, in the T2N1Mx stadium 
(May 2010) (Figure 1).
Medical history revealed a condition after three 
removals of salivary gland tumors (1979, 1986, and 
1989), benign prostatic hyperplasia, type 2 diabetes 
(treated with insulin), hypertension (second degree 
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according to the Polish Society of Hypertension), 
and chronic kidney disease in the second stage. In 
the past (2006), due to aortic stenosis, vascular 
treatment was performed that included stent place-
ment in the left renal artery and endarterectomy of 
the common carotid artery and the right internal 
carotid artery. After the cancer was diagnosed, pan-
creatoduodenectomy was performed on the patient 
using the Whipple method (June 2010). Once dis-
charged from hospital, the patient attended regular 
checks at the Oncology Center in Bydgoszcz. After 
one year (September 2011), in FUSION PET (PET/
CT) examination and in computed tomography (CT 
scans), recurrence was demonstrated. The patient 
was qualified for LFP chemotherapy (calcium foli-
nate, fluorouracil, cisplatin). In a CT check in 
December 2011, no progression was demonstrated 
in relation to the previous check. During chemo-
therapy (March 2012), deep vein thrombosis in the 
lower limbs and visceral vein thrombosis occurred. 
Anticoagulants were included and then discontin-
ued because of occurrence of a peri-cerebral hema-
toma (subdural) in the forehead and left vertex area 
(April 2012). For this reason, in April 2012, an 
operation was performed on the patient to remove 
a subcaudal hematoma, with complications con-
sisting of bleeding into the operating space that 
required reoperation and use of short respirother-
apy with anti-edematous treatment in the Intensive 
Care Unit.
After efficient respiration was achieved, the 
patient was extubated and rehabilitation was 
implemented and continued at the Rehabilitation 
Unit (7–31 May 2012). Paresis of the right limbs 
was alleviated, the overall fitness and motor coor-
dination were improved, but aphasia, mostly 
motor, remained. During that hospitalization, the 
patient experienced abdominal pain, localized 
Table 1. Neurochemical influences that affect activity of thermoregulatory preoptic hypothalamic neurons.3
Influence Effect Clinical implications (examples)
Serotonin (5-HT2 receptor) Hyperthermia Serotonin syndrome, IL-1β induced fever, antipsychotic-induced 
hypothermia*
Serotonin (5-HT1 receptor) Hypothermia SSRI-induced sweating,† postoperative hypothermia, hypoxia-
induced hypothermia
Dopamine (D2 receptor) Hypothermia Bromocriptine-induced hypothermia, neuroleptic malignant 
syndrome‡
Norepinephrine (α1 receptor) Hypothermia Isoflurane-induced hypothermia
Opioids  
μ receptor Hyperthermia Fentanyl reduces shivering threshold during epidural anesthesia
κ receptor Hypothermia Hypothermia during opioid overdose
Acidosis Hyperthermia Heat shock
Prostaglandin E2 Hyperthermia Fever
*Risperidone and other antipsychotic agents block 5-TH2 receptors and could lead to hypothermia.
†Cyprocheptadine may reduce SSRI-induced sweating, presumably by blocking 5-TH1 receptors.
‡This disorder may reflect blockade of D2 receptors in hypothalamus.
SSRI, selective serotonin reuptake inhibitors.
Figure 1. Diagram showing the history of the disease.
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mostly in the epigastrium, which gradually 
increased. This is why, after his discharge from the 
hospital, the patient was treated by the oncologist 
with a mixture of analgesics (including papaver-
ine, codeine, and metamizol). The pain treatment 
turned out to be insufficient and the patient was 
provided with home hospice care (Table 2). During 
the first visit on 6 June 2012, the palliative medi-
cine physician recommended a 50-mg dose of 
tramadol every 6–8 h, orally (in a short-acting 
preparation). At that time, the patient was already 
taking anticonvulsant medication due to epileptic 
seizures after a neurosurgical procedure (valproate 
in a 2 × 500 mg dose). On 7 June 2012, the result 
of urine culture was obtained which demonstrated 
the presence of Morganella morganii (103–104); 
consequently, a decision was made to include cip-
rofloxacin in the 2 × 500 mg oral dose for a period 
of five days. Due to low tolerance of the therapy, 
the pharmacotherapy was modified and trime-
toprim was used (240 mg/5 mL suspension, rec-
ommended 5 mL every 12 h), which was 
maintained for the next nine days (until 21 June 
2012). Due to the deteriorating pain control, on 15 
June 2012, the treatment was modified and mor-
phine in a 0.5% water solution was included with 
the recommended dose of 0.5 mL of the solution 
(2.5 mg) orally as needed. Initially, the ad hoc 
doses resulted in good control of the pain and then, 
after six days, due to the recurring pain, oral mor-
phine of regular doses (5 mg every 4 h) was started. 
On 21 June 2012 (the first day of regular morphine 
intake), after about 12 h, fever occurred (>38°C) 
without the characteristics of an infection. 
However, the practitioner decided that the most 
likely cause of the fever is infection of the urinary 
tract; consequently, he recommended amoxycillin 
with clavulanic acid (2 × 1 g, orally) for seven 
days and, due to deteriorated verbal contact, dexa-
methasone was administered in the morning in the 
dose of 4 mg, subcutaneously. In spite of the ther-
apy, the fever continued and caused a deterioration 
in the contact with the patient as well as strong 
shivers (also, an epileptic seizure cannot be 
excluded as, according to family members, a loss 
of consciousness also occurred). After morphine 
intake was discontinued (after less than 24 h of 
treatment) and use of tramadol was resumed in a 
larger doze than initially, the body temperature 
normalized. Three more attempts were made to 
include morphine (at intervals of 3–4 days) in reg-
ular doses taken every 4 h caused fever following 
strong shivers about 12 h after the first dose. In 
periods of high temperature, family members gave 
paracetamol and metamizole to the patient and 
applied cold compresses, which resulted in a 
reduction in the body temperature. For fear that 
the fever might occur again, morphine was discon-
tinued and a tramadol dose of 50–75 mg in drops 
was resumed – most often given only as necessary. 
Later, a controlled release form was used up to the 
dose of 400 mg/day. After several days of regular 
administration of the maximum dose of tramadol, 
fever following shivers occurred again. On 7 
August 2012, the opioid was replaced with con-
trolled-release tablets of oxycodone, with the rec-
ommended dose of 2 × 10 mg. The pain-control 
effect was very good but after the third dose (1.5 
days), high fever occurred with accompanying 
significant drowsiness, as well as deteriorated 
contact and apathy. Due to the undesirable effects 
and concern that they would intensify, tramadol 
Table 2. Follow-up examinations.
10 July 2012 23 August 2012 12 September 2012
WBC (thousand/µL) 6.12 7.38 16.53 ↑
HGB (g/dL) 9.2 ↓ 8.4 ↓ 9.5 ↓
PLT (thousand/µL) 180 105 ↓ 121
creatinine (mg/dL) 1.70 ↑ 1.51 ↑ 1.24 ↑
eGFR 43 49 > 60
Na (mmol/L) 137.5 136.9 135.5
K (mmol/L) 3.97 4.13 4.30
Ca 2.35  
CRP (mg/L) 90.69 ↑  
AlAT (IU/L) 29.5  
AspAT (IU/L) 39.1  
↑- above reference values, ↓- below reference values.
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was used once again to control pain. Eventually, on 
17 August 2012, morphine was used again in the 
initial dose of 10 mg a day, subcutaneously, admin-
istered every 4 h. Within four days, shivers and 
body temperature occurred again; their intensity 
was similar to the previous level (mostly low-grade 
fever up to the maximum temperature of 38°C). 
The symptoms were observed about 2 h after mor-
phine was administrated. According to the family 
members’ account, this was accompanied by slight 
muscle stiffness, which caused problems with get-
ting out of bed, without any consciousness disrup-
tions or convulsions. Administration of morphine 
was continued subcutaneously until death as 
needed (it sufficed for as long as 8 h) and later it 
was required at shorter intervals due to the end-of-
dose pain (every 6 h). In the terminal phase of life, 
the patient did not receive antibiotics, despite the 
increased body temperature and leukocytosis 
determined in the last blood morphology test per-
formed on 12 September 2012 (Table 2). The 
patient died on 24 October 2012.
While in care, the patient underwent follow-up 
examinations (presented in Table 2 below).
Discussion
There are different interpretations of the distur-
bances in thermoregulation in patients with 
advanced cancer. A definitive determination of the 
causes of fever in a patient suffering from advanced 
cancer may be difficult and, as the above case dem-
onstrated, is often based on empirical analysis.
Potential factors that predispose patients in this 
population to have fever are changes in immuno-
competence (the cancer itself, malnutrition, the 
implemented therapy), the mechanical effect of the 
cancer’s progression (infiltration of tissues, fistulas, 
impact on natural biological barriers), placement of 
foreign objects and their impact on the mucosa, 
repeated antibiotic treatment, discontinuation of 
used medicines (opioids, benzodiazepines).4
The most frequent cause of fever in this group of 
patients, in particular in those undergoing chemo-
therapy, is infection.5 It is assumed that cases of 
fever in a patient with cancer (including neutro-
penic fever) should be associated with an infection 
and only once an infection has been excluded 
should another cause be looked for. The second 
most frequent cause of fever is cancer itself (27%).6 
Paraneoplastic fever can actually occur in patients 
with any cancer, in particular during the progres-
sion of the disease. Although it has been known for 
years that cancer cells, despite lack of co-existing 
infection, produce pyrogens, the mechanism lead-
ing to paraneoplastic fever remains unknown. 
Factors that cause fever include interleukin 1α (IL-
1α), interferon α (INF-α), tumor necrosis factor α 
(TNF-α), IL-6, oncostatin-M, cardiotrophin, and 
leukemia inhibitory factor. Pyrogens can act 
directly on the thermoregulatory center in the 
hypothalamus and, most of all, on the front preop-
tic nuclei, thus raising the thermal value by chang-
ing the activity of brain cyclooxygenasis (COX). 
In endothelial cells and cells surrounding vessel 
walls of the blood–brain barrier, post-inflamma-
tory cytokines induce production of prostaglandin 
E2. It is the basic central fever mediator and its syn-
thesis is catalyzed by, among others, phospholipase 
A2 and COX. In patients with metastases in the 
brain, paraneoplastic fever may also result from 
direct damage to the brain tissue and the ensuing 
activation of phospholipase A2.7
It can be difficult to distinguish between infec-
tion-related fever and other types of fever, in par-
ticular paraneoplastic fever. In the case of 
infection-related fever, one rather expects tempera-
ture surges with accompanying shivers and sweat-
ing. In the case of paraneoplastic fever, more 
common is the constant sense of heat and sweat-
ing, generally without shivers, tachycardia, and 
mental (cognitive, consciousness) changes. Unlike 
infection-related fever, paraneoplastic fever does 
not respond to acetylsalicylic acid and acetami-
nophen. However, it recedes after naproxen is 
administered (naproxen test) and after other non-
steroidal anti-inflammatory drugs (NSAIDs), such 
as ibuprofen and diclofenac.8–10 Chang’s paraneo-
plastic fever diagnostic criteria are still considered 
to be up-to-date (Table 3).11
In the case described here, the influence of uri-
nary tract infections and the cancer itself, as well as 
brain damage (as a result of bleeding into the cen-
tral nervous system and two neurosurgical opera-
tions), venous thrombosis, and the medications 
taken, must not be excluded. In the initial period in 
particular, infection-related fever was very likely 
because of the “positive” urine culture. This is why 
another antibiotic was introduced (despite the lack 
of other symptoms indicating urinary tract infec-
tions), which did not result in a reduction of the 
fever.
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An analysis of the time relationship between the 
temperature increase incidents and the use of opi-
oids indicates opioid-related fever. Opioid-related 
fever is an immensely rare phenomenon and there-
fore it is nearly impossible to define the typical 
course of the fever and the accompanying symp-
toms. Given the same mechanism of its occurrence, 
one can try to explain it in the following manner: 
stimulation of opioid receptors of the mi (μ) type 
on the immunocompetent cells in some genetically 
predisposed patients leads to expression of proin-
flammatory cytokines which, by increasing the 
production of endogenous pyrogen, can stimulate 
the hypothalamus to cause fever.
Also, it is possible that as a result of opioid use, 
changes may take place in the range of functioning 
of the central nervous system structures that are 
responsible for thermoregulation. The mechanism 
of hyperthermia induced by opioids can be com-
pared to opioid-induced hyperalgesia (OIH). The 
latter, observed in certain patients treated with opi-
oid, is manifested by increased sensitivity to pain 
stimuli despite increased doses.12,13 One of the the-
ories concerning OIH points at the emergence in 
the reticular formation of “on” type neurons instead 
of “off” type neurons. It is also possible that, due to 
the universal presence of opioid receptors in brain 
structures, opioids can also directly influence the 
centers responsible for thermoregulation. A partial 
explanation of this is the fact that a pure agonist of 
mi (μ) type receptors (without a ceiling effect) can 
induce hyperthermia, while opioids from the sec-
ond step of the analgesic ladder, which do have the 
ceiling effect, do not demonstrate this ability.14 In 
the case described here, the effectiveness of anti-
pyretic drugs was observed, which possibly con-
firms this mechanism. Unfortunately, during fever 
occurrences, the patient’s C-reactive protein 
(CRP), which is an unspecific marker of the acute 
phase of inflammation, was not regularly con-
trolled. The only test was performed in August 
2012 (after the incidents involving fever associated 
with administration of the opioid) and the meas-
ured value was about 90 mg/L. However, it is not 
known if earlier determinations of this marker 
would actually have proven to be helpful. In a pro-
spective analysis covering patients with solid 
tumors mostly of the head and the neck, Penel et al. 
evaluated the diagnostic value of the CRP concen-
tration. They found that CRP concentration was 
not significantly different in the case of infection-
related fever and paraneoplastic fever.15 An inter-
esting observation pertains to differences in the 
increase of the CRP in patients without cancer and 
with cancer in the course of an infection.1,15 In the 
former group, as early as in the first 8 h of the 
infection, the value often increases above 100 
mg/L, and after 48 h of effective antibiotic therapy 
it drops quickly. On the other hand, in the latter 
group, both the increase of the CRP and its decrease 
during antibiotic therapy are not so significant. 
This is due, among others, to other groups of medi-
cines used at the same time (steroids, NSAIDs, 
chemotherapy). Interestingly, high CRP values can 
be observed in some patients with advanced cancer 
without accompanying infections. Consequently, 
concentration of this acute-phase protein is non-
specific both in infections and in cancer, especially 
in the advanced stadium of the latter.
A useful marker to distinguish the causes of 
temperature increase in patients with advanced 
cancer appears to be procalcytonin (PCT) (which 
was not determined in the case described herein), 
whose significantly higher concentrations were 
found to be present in infection-related fever.15 
However, in no patients with paraneoplastic fever 
did the concentration reach the value of 2 ng/mL; 
consequently, in the opinion of the researcher, the 
Table 3. Criteria for paraneoplastic fever.15
I Temperature over 37.8°C at least once each day
II Duration of fever over two weeks
III Lack of evidence of infection on:
A. Physical examination
B.   Laboratory examinations, e.g. sputum smears or cultures, cultures of blood, urine, stool, bone marrow, spinal fluid, 
and discharge from local lesions
C. Imaging studies, e.g. chest radiograph or CT scans of the head, abdomen, and pelvis
IV Absence of allergic mechanisms, e.g. drug allergy, transfusion reaction, or radiation and chemotherapeutic drug reaction
V Lack of response of fever to an empiric, adequate antibiotic therapy for at least seven days
VI Prompt, complete lysis of fever by the naproxen test with sustained normal temperature while receiving naproxen
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predictive value of PCT in diagnostics of this type 
of fever is 100% negative.
Interactions between different neurotransmitters 
and neuromodulators, such as norepinephrine, 
dopamine, serotonin, acetylcholine, prostaglandin 
E1, GABA, and opioids, are important to the regu-
lation of body temperature on the central level. If 
the opioid system takes part in thermoregulation 
control in mammals, then endogenous opioid pep-
tides and opioid medicines, such as morphine, can 
influence the body temperature. Hyperthermia and 
hypothermia caused by an opioid are the effects of 
actions on the opioid receptor by the μ, κ, and delta 
receptor agonists; therefore, both these phenomena 
can be blocked by the antagonists. Also, in both 
cases tolerance and cross-tolerance may develop.16
Morphine administered (in the room tempera-
ture of the laboratory) in small doses caused hyper-
thermia in rats by activating the mi receptors, while 
in larger doses it causes hypothermia by stimulat-
ing the kappa type receptors (κ).17–20 Perhaps this 
impact on the mi receptors could explain the pres-
ence of hyperthermia in the patient described 
herein. Tramadol, morphine, and oxycodone (the 
latter two in low doses) are antagonists that act 
mainly through opioid receptors of the mi (μ) type.
The fever mechanism must also include pathol-
ogy within the central nervous system which was 
present in the patient described herein. Tests on 
animals have demonstrated that interactions 
between opioid receptors and the stimulating and 
inhibitory amino acids are important to the survival 
of the cells damaged by induced hyperthermia and, 
consequently, to the functioning of the brain.21 
Tests performed on rats indicate that blocking of 
opioid receptors significantly changes the neuro-
transmission of amino acids and causes neuropro-
tection. On the other hand, breaking of the 
blood–brain barrier increases the risk of cognitive 
dysfunction of the brain, cerebral edema, and brain 
damage induced by hyperthermia.21 One can sus-
pect that in the patient described herein the damage 
to the blood–brain barrier caused by the pericere-
bral hematoma and the two neurosurgical opera-
tions were conducive to the aggravation of the 
symptoms of hyperthermia (cognitive disruptions, 
strong shivers, and loss of conscience) and to the 
occurrence of fever as a result of small doses of 
agonists of the mi opioid receptor.
In conclusion, diagnosis of fever and selection 
of the target procedure can be difficult in the case 
of patients with advanced cancer and simultane-
ous occurrence of many potential causes of ther-
moregulation disorders. At present, opioid-related 
fever can only be diagnosed by way of elimina-
tion (in particular of infection-related fever and 
paraneoplastic fever) and is based on an analysis 
of the time relationship between the use and dis-
continuation of use of opioids and the distur-
bances in thermoregulation. One must also 
consider whether another attempt to use a drug (a 
provocation attempt) causes similar symptoms 
and whether discontinuation of a drug results in 
remission of the problem and if so, then after what 
time. In the patient described herein, repeated use 
of morphine (but also oxycodone and tramadol, 
the latter in the maximum dose) caused the occur-
rence of the same symptoms after three succes-
sive doses of the medicine administered at 4-h 
intervals (after about 12 h). Clinically, most often 
the temperature increased above 38°C, with 
accompanying disruptions in the central nervous 
system in the form of deteriorated contact with 
the surroundings. In patients with advanced pan-
creatic cancer, fever may occur spontaneously 
without any relation to a potential infection fac-
tor, which is confirmed by lack of leukocytosis 
with an increase of the CRP.
Declaration of conflicting interests
The authors declare that there is no conflict of interest.
Funding
This research received no specific grant from any fund-
ing agency in the public, commercial, or not-for-profit 
sectors.
References
 1. Jabłońska EM (2008) The theromoregulatory dis-
orders in cancer patients. (English translation here) 
In: Krzemieniecki K (ed.) Adjunctive Therapy in 
Oncology. Poznań: Termadia, pp. 106–135.
 2. Romanovsky AA (2006) Thermoregulation: Some 
concepts have changed. Functional architecture of 
the thermoregulatory system. American Journal of 
Physiology. Regulatory, Integrative and Comparative 
Physiology 292: R37–R46.
 3. Bennarroch EE (2007) Thermoregulation: Recent 
concepts and remaining questions. Neurology 69: 
1293–1297.
 4. Zhukovsky DS (2002) Fever and sweats in the patient 
with advanced cancer. Hematology/Oncology Clinics 
of North America 16: 579–588.
104 International Journal of Immunopathology and Pharmacology 30(1)
 5. Penel N, Degradin M, Frippiat F, et al. (2000) Existe-
t-il des critères diagnostiques en faveur d’une fièvre 
paranéoplasique? La Revue de Medecine Interne 21: 
684–692.
 6. Toussaint E, Bahel-Ball E, Vekemans M, et al. (2006) 
Causes of fever in cancer patients (prospective study 
over 477 episodes). Support Care Cancer 14: 763–796.
 7. Johnson M (1996) Neoplastic fever. Palliative 
Medicine 10: 217–224.
 8. Chang JC (1998) Antipyretic effect of naproxen and 
corticosteroids on neoplastic fever. Journal of Pain 
and Symptom Management 3: 141–144.
 9. Tsavaris NJ, Zinelis A, Karabelis A, et al. (1990) A 
randomized trial of the effect of three non-steroid anti-
inflammatory agents in ameliorating cancer-induced 
fever. Journal of Internal Medicine 228: 451–455.
 10. Economos K, Lucci JA, Richardson B, et al. (1995) 
The effect of naproxen on fever in patients with 
advanced gynecologic malignancies. Gynecologic 
Oncology 56: 250–254.
 11. Zell JA and Chang JC (2005) Neoplastic fever: A 
neglected paraneoplastic syndrome. Supportive Care 
in Cancer 13: 870–877.
 12. Mao J (2011) Overview on opioid-induced hyper-
algesia (Chapter 1). In: Mao J (ed.) Opioid Induced 
Hyperalgesia. New York, NY: Informa Healthcare 
USA, Inc., pp. 1–8.
 13. Mao J (2002) Opioid-induced abnormal pain sensitiv-
ity: Implications in clinical opioid therapy. Pain 100: 
213–217.
 14. Grassi L and Riba M (eds) Psychopharmacology in 
Oncology and Palliative Care. Berlin: Springer.
 15. Penel N, Fournier C, Degardin M, et al. (2001) Fièvre 
et tumeur solide: Valeur diagnostique de la proc-
alcitonine et de la protéine C réactive. La Revue de 
Medecine Interne 22: 706–714.
 16. Adler MW, Geller EB, Rosow CE, et al. (1988) The 
opioid system and thermoregulation. Annal Review of 
Pharmacology and Toxicology 28: 429–449.
 17. Chen XH, Geller EB, DeRiel JK, et al. (1996) Antisense 
confirmation of mu- and kappa-opioid receptor media-
tion of morphine’s effects on body temperature in rats. 
Drug and Alcohol Dependence 43: 119–124.
 18. Spencer RL, Hruby VJ and Burks TF (1988) Body tem-
perature response profiles for selective mu, delta and 
kappa opioid agonists in restrained and unrestrained 
rats. Journal of Pharmacology and Experimental 
Therapeutics 246: 92–101.
 19. Rosow CE, Miller JM, Pelikan EW, et al. (1980) Opiate 
and thermoregulation in mice. I. Agonists. Journal of 
Pharmacology and Experimental Therapeutics 213: 
273–283.
 20. Ovtcharov R and Yakimova K (1984) [Opiates, 
opioid receptors and thermoregulatory changes]. 
Eksperimentalna Meditsina i Morfologiia 23: 205–210.
 21. Sharma HS (2007) Interactions between amino acid 
neurotransmitters and opioids receptors in hyper-
thermia-induced brain pathology (Chapter 15). In: 
Sharma HS (ed.) Neurobiology of hyperthermia. 
Amsterdam: Elsevier, pp. 295–318.
